From ASH 2024 to Practice: Implementing Bispecific Therapies in B-Cell Lymphomas
Panelists discuss how the latest data from the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) on bispecific therapies for B-cell lymphomas, including epcoritamab, mosunetuzumab, and odronextamab, influence treatment strategies, address toxicity management, and highlight the challenges and opportunities in expanding access to these therapies across academic and community settings.
Episodes
December 20th 2024EP. 1: ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas
Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.
